ABSTRACT Background To investigate the oral semaglutide use among Mexican adults with type 2 diabetes. Methods PIONEER REAL was a multinational, open‐label study evaluating oral semaglutide in patients without prior injectable glucose‐lowering treatment. This analysis focuses on data from Mexico. Results Of 177 patients, 139 (78.5%) completed the study and 111 (62.7%) remained on treatment at the end. The mean (SD) age was 54.0 (10.96) years, 57.6% were women, 59.3% had obesity, and 44.6% had a medical history of cardiovascular disease. The average T2D duration was 5.7 years (SD 6.45), with mean HbA1c at 8.1% (SD 1.85). At week 38, mean HbA1c had decreased to 6.8% (estimated mean SE change in HbA1c, −1.3% 0.11; p < 0.0001), and body weight had decreased from 87.8 kg (19.34) to 85.3 kg (estimated mean SE change in body weight, −4.3 kg 0.56; p < 0.0001), as had waist circumference (estimated mean SE change, −3.7 cm 0.54; p < 0.0001). Additionally, satisfaction with treatment increased over time. Only 6.2% of patients had adverse events leading to withdrawal of semaglutide. Conclusions According to this real‐world study, starting oral semaglutide treatment in Mexico is associated with notable decreases in both HbA1c levels and body weight among patients with type 2 diabetes. Satisfaction with treatment also improved significantly. Moreover, the safety profile is consistent with that of previous studies. Trial Registration: ClinicalTrials.gov registration NCT04601753.
González-Gálvez et al. (Wed,) studied this question.